Last $0.44 USD
Change Today -0.005 / -1.12%
Volume 317.1K
COCP On Other Exchanges
As of 8:10 PM 12/26/14 All times are local (Market data is delayed by at least 15 minutes).

cocrystal pharma inc (COCP) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/16/14 - $0.74
52 Week Low
08/5/14 - $0.25
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for COCRYSTAL PHARMA INC (COCP)

Related News

No related news articles were found.

cocrystal pharma inc (COCP) Related Businessweek News

No Related Businessweek News Found

cocrystal pharma inc (COCP) Details

Cocrystal Pharma, Inc., a preclinical-stage biopharmaceutical company, intends to develop medicines for use in treating human viral diseases. The company focuses on developing inhibitors of viral replication enzymes that are essential to viral replication. It is developing antiviral therapeutics for human diseases, including Hepatitis C virus, Influenza virus, Rhinovirus, Dengue Virus, and Norovirus. The company also develops targeted in-house chemical libraries consisting of antiviral compounds of various types, including non-nucleoside inhibitors, metal-binding inhibitors, and fragments. In addition, it is developing compounds that inhibit HCV helicase, an enzyme that is essential for hepatitis C viral replication. The company was founded in 2007 and is headquartered in Bothell, Washington.

cocrystal pharma inc (COCP) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

cocrystal pharma inc (COCP) Key Developments

Cocrystal Pharma, Inc. Announces Resignation of Roger Kornberg and Sam Lee from the Board of Directors

Cocrystal Pharma, Inc. announced that on November 22, 2014, Dr. Roger Kornberg and Dr. Sam Lee resigned from the board of directors of the company.

Cocrystal Pharma, Inc. Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2014

Cocrystal Pharma, Inc. reported financial results for the third quarter and nine months ended September 30, 2014. During the three months period ended September 30, 2014, the company had a loss from operations of $1.2 million. During the nine months period ended September 30, 2014, the company had a loss from operations of $4.1 million. Cash used in operating activities was approximately $4.2 million for the nine months ended September 30, 2014.

Cocrystal Pharma, Inc. Develops Novel Ebola Screening Technology

Cocrystal Pharma, Inc. reported that it has developed what it believes to be the first high-throughput screening technology for inhibitors of a key essential Ebola virus gene product.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
COCP:US $0.44 USD -0.005

COCP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for COCP.
View Industry Companies

Industry Analysis


Industry Average

Valuation COCP Industry Range
Price/Earnings 53.2x
Price/Sales -- Not Meaningful
Price/Book 13.6x
Price/Cash Flow 53.2x
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact COCRYSTAL PHARMA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at